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Purpose: In an era of increasing prostate cancer incidence and earlier detection, the assessment of
clinical signiﬁcance of prostate cancer is critical. Minimally invasive therapies are increasingly being
investigated in localized prostate cancer.
Methods and results: In this review, we discuss the current status of magnetic resonance imaging
targeted fusion prostate biopsy and focal therapy for prostate cancer, its rationale, and techniques.
Conclusion: Focal therapy offers a promising outlook for prostate cancer treatment, with the goal of
effectively achieving cancer control while minimizing morbidity. Long term studies are needed.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Rationale for focal therapy for prostate cancer
With the widespread use of prostate-speciﬁc antigen (PSA)
screening and increasing life-expectancy, more men are being
diagnosed with localized, low-risk, low-grade prostate cancer.1
These patients can be managed with deﬁnitive therapy, including
radical prostatectomy (RP) or radiation therapy (RT). However,
these radical therapies are associated with signiﬁcant complication
risks and side effects, which may be unsuitable for or undesired by
the patient with low-risk prostate cancer. In an era of increasing
prostate cancer incidence and stage migration toward earlier dis-
ease, appropriate management of the disease requires assessment
of the risk of clinical signiﬁcance of the disease. Minimally invasive
therapies are increasingly being investigated as an alternative.
Prostate cancer is relatively slow growing, with doubling times
for local tumors estimated at 2e4 years. Some prostate cancers
prove to be so small, low-grade, and noninvasive that they appear
to pose little risk to the patient, and are considered indolent. A
recent review suggests that 49% of men undergoing RP have
pathological features in the RP specimen consistent with an insig-
niﬁcant or indolent cancer (organ-conﬁned cancer < 0.5 mL, no
Gleason Grade 4 or 5 component).2
Up to 33% of patients on active surveillance (AS) eventually fall
out of surveillance and undergo deﬁnitive treatment after 2e5
years because of initial understaging or disease progression.3enter, 150 East 32nd Street,
rshall).
ier B.V. on behalf of Prostate InteSeventy-three percent of patients initially enrolled in AS who un-
dergo RP have a signiﬁcant cancer on RP specimens.4 Other
downsides of AS include the mental and emotional burden and
anxieties associated with untreated cancer. Therefore, AS is an
option for only a select group of men.
In order to cure and control localized prostate cancer, the concept
of focal therapy has emerged. Focal therapy is the middle ground
between AS and radical therapy, offering much less morbidity with
cancer control. Focal destruction of cancer, with preservation of the
surrounding organ, has already been used widely in the oncological
treatment of kidney, liver, breast, and brain.
The concept of focal therapy is relevant for prostate cancer in a
number of ways. First of all, there is strong evidence that the vast
majority of metastases ﬁnd their origin in the same prostate cancer
cell clone, derived from the same lesion called the index lesion.5,6
Histopathological features of the index lesion predict the clinical
behavior of the entire gland despite multiple synchronous tumors
in >90% of patients.7,8 While prostate cancer is typically multifocal
with clonal heterogeneity of prostate cancer within the gland, not
all tumors within a single gland have the potential for lethality.
Historically, the threshold for clinically signiﬁcant disease, capable
of metastatic progression, has been set at 0.5 mL, with some
Gleason grade component  4.7,8 It has been shown that in >80%
patients with an index lesion of cancer, the aggregate volume of
secondary tumors is < 0.5 mL.7,8 Since most metastatic cancers
originate from a single clonal cancer cell, it would be reasonable
and effective to identify and target this potentially lethal lesion
with focal therapy. Thus, selective treatment of clinically signiﬁcant
disease, with acceptance of residual, insigniﬁcant disease mayrnational. This is an open access article under the CC BY-NC-ND license (http://
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data exist regarding outcomes of focal therapy.9
2. Candidate selection/risk strata
The selection of patients is a critical element of the challenges of
focal therapy adoption and use. Patient candidate selection should
ultimately be based on the intent of focal therapy. In those patients
inwhom focal therapy is utilized for cure, the disease should be low
risk and low volume in a targetable area of the prostate. The ideal
patient would be one with low-stage, low-risk prostate cancer that
could be completely eradicated.
Focal therapy can be used with the intent of disease control.
A therapy to control cancer would prolong the natural history of
prostate cancer and delay the morbidity of radical treatment. In
this situation, focal therapy would treat the dominant lesion or
index lesion. In doing so, focal therapy could prolong the period of
surveillance, and mitigate the uncertainties and anxieties of pure
AS.10
Lastly, focal therapy could be utilized as a part of a multimodal
treatment approach in the high-risk patient who would likely fail
single-modality therapy, but avoid the morbidities associated with
radical treatment. Use of focal therapy for noncurative intent has
yet to be validated and studied.10
Up tonow,most trials have includedonly low-risk patients under
the premise that men with low-risk disease are at little risk of sys-
temic relapse, and thus, local disease control can be a measure of
treatment efﬁcacy.11 As focal targeting methods develop, there is a
stronger impetus to treat men who are at risk of disease-related
mortality, as they may be the ones to beneﬁt the most. In treating
only low-risk patients, one can argue that the beneﬁt of therapymay
never be proven, as these patients would have fared well on sur-
veillance anyway. However, most focal therapy trials include low-
risk patients due to the known risk of 30e40% upgrading of surgi-
cal pathology from biopsy pathology. At this time, it is not clear if
Gleason 7 (3 þ 4) with small proportion of 4 has a similar favorable
outcome as Gleason 6. Gleason 7 (3 þ 4) has an intermediate risk of
relapse, and therefore gives focal therapy the opportunity to treat
and prevent prostate cancer relapse. The heterogeneity in biological
behavior of Gleason 7 tumors has been shown. Gleason score 4 þ 3
tumors had an increased risk of progression (compared to Gleason
3 þ 4 tumors) independent of stage and margin status, and were
predictive of metastatic disease (as opposed to Gleason 3 þ 4 tu-
mors).12 In addition, Gleason 4 þ 3 tumors were more strongly
associated with extraprostatic extension and upgrading on surgical
specimens than Gleason 3 þ 4 tumors were.13 Gleason 7 (4 þ 3)
tumors have a similar risk of relapse as Gleason 8 (4 þ 4) tumors.
Candidate selection relies heavily on accurate patient identiﬁ-
cation and risk stratiﬁcation. Risk stratiﬁcation can be used to
assess the chance of unfavorable pathology, poor oncological
outcome, biochemical recurrence, and survival. Low-risk category
patients have a low risk of short-term cancer mortality. The
D'Amico classiﬁcation is the most common classiﬁcation used to
stratify the risk of biochemical recurrence after radical treatment.14
The percentage of Gleason 4 tumors is sharply correlated with
outcome. Stamey et al suggested that 20% of Gleason 4/5 tumors
on biopsy (which is correlated to the same percentage of Gleason
4/5 tumor in RP specimens) represents the lower-risk subset of
those harboring a Gleason 4 pattern.15
3. Limitations of standard systematic biopsy
Transrectal ultrasound (TRUS)-guided biopsy using a 12-core
sampling scheme is the standard approach for prostate cancer
diagnosis.16 Performing TRUS biopsy for focal therapy selection isfelt to be inadequate due to the risk of underestimating disease risk,
volume, and focality.17 It has been shown that if a 12-core biopsy
shows unilateral disease, there is a 75% chance of a tumor on the
contralateral side.18 Focal therapy selection and planning requires
accurate assessment of these parameters.
The success of focal therapy clearly depends on the ability to
detect the extent and laterality of prostate cancer and then accu-
rately target it. There is no consensus currently on patient selection
protocols for focal therapy. The reason for this is twofold. So far, there
has been a lack of adequate biopsy techniques that can accurately
detect prostate cancer lesions, and also a lack of imaging modalities
to complement inadequate biopsies. Detection relies upon reduc-
tion of sampling error through the number of samples taken and the
location of the samples in the prostate.19,20 In men with negative
biopsies, repeat biopsy is often used up to ﬁve or six times before
detection e sampling error is overcome through increased sam-
pling. This approach of random sampling leads to three intrinsic
errors: (1) underdetection bymissing a potentially lethal cancer; (2)
overdetection by identifying a small nonlethal cancer; and (3)
misclassiﬁcation by identifying an apparent low-risk cancer in
someone with high-risk disease. Even extended TRUS-guided
saturation biopsy appears to be inadequate in the proper selection
of patients for focal therapy.21 Transperineal (TP) biopsywith three-
dimensional (3D) mapping was thought to improve on cancer
localization, as samples are taken every 5 mm throughout the vol-
umeof theprostate using a brachytherapy template grid under TRUS
guidance. However, >61% of patients diagnosed with unilateral
cancer on TP biopsy were found to have bilateral disease, and 27%
were upstaged in Gleason score.22,23 Moreover, TP biopsy has fallen
out of favor due to time demands, need for anesthesia, and cost.
Biopsy sampling error may be better addressed through locali-
zation of the cancer region by imaging than through simply
increasing sampling. To achieve this goal, fusion biopsy has evolved
as the standard for accurate maximal fusion of disease foci, ac-
cording to a consensus panel.24
4. MRI-targeted fusion biopsy
The evolution of MRI to multiparametric MRI (MP MRI) is an
important innovation for focal therapy in prostate cancer. A typical
MP MRI includes T1-weighted sequences with dynamic contrast
enhancement (DCE) sequence, T2-weighted sequences, and
diffusion-weighted imaging (DWI) sequences performed by torso
phased-array coils.25MPMRI is the best noninvasive imaging test for
the visualization of cancer foci in prostate. While MP-MRI may not
detect all foci of disease in the prostate, it appears to better detect
clinically signiﬁcant foci based upon Gleason score and cancer vol-
ume.26 For signiﬁcant lesions, as deﬁned previously, sensitivity and
speciﬁcity of MP MRI are up to 90%.27 In one study, sensitivity,
speciﬁcity, negative predictive value, and accuracy for peripheral
zone cancer detection at biopsywere, respectively,100, 51.4,100 and
66.7%.28 In a series of 83patients studiedbymultiparametric imaging
(T2 þ DWI þ DCE) at 1.5 T before biopsy, MRI was associated with a
high sensitivity, speciﬁcity, and accuracy for detection of prostate
cancer of 95%, 74%, and 86%, respectively.29 MP MRI, as a 3D tech-
nique, can determine prostate cancer foci location within the gland
and volume/shape of the tumor and can be used to target lesions.
MRIeultrasound fusion technology has recently allowed tar-
geted biopsies to cancer-suspicious regions noted on MRI. The
Artemis spatial tracking and computerized biopsy system functions
to record the position of biopsy cores within a 3D template
reconstruction of the prostate. Computer software allows fusion of
the patient's MRI with real-time ultrasound while performing the
Artemis biopsy, allowing targeting of the abnormal region on MRI
during Artemis biopsy.
Fig. 2. Pre-cryoablation 3T magnetic resonance imaging: anterior prostate tumor.
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would have an abnormality suspicious for PC on MP MRI. Targeted
biopsies of these areas would lead to cancer identiﬁcation in ~65%
of those men.30e32 While overall cancer detection rates are lower
with targeted than systematic biopsy, the majority of cancers
missed on targeted biopsy are deemed clinically insigniﬁcant
(likely nonlethal) as measured by current pathological classiﬁca-
tion methods.30,31,33,34 MRI-targeted biopsy results in a 42% clini-
cally signiﬁcant cancer detection rate.30 Haffner et al studied
extended systematic biopsies and MRI-targeted biopsies in the
same patient in their study group. Targeted biopsies detected 16%
more Grade 4e5 cases and better quantiﬁed the cancer than did
extended systematic biopsies, with cancer lengths of 5.56 mm
versus 4.70 mm (P ¼ 0.002).31 In a recent study by Sonn et al35 of
patients with negative prior biopsies or with prostate cancer on AS,
the addition of MRIeUS fusion targeted biopsies to systematic bi-
opsies increased the rate of diagnosis of all cancers, as well as
Gleason 7 cancer. Thirty-eight percent of men with Gleason 7
cancer had disease detected only via targeted biopsies of lesions
identiﬁed on MRI.35 In men with clinically suspected prostate
cancer, a biopsy using MRI to inform the sampling was associated
with a 42% clinically signiﬁcant cancer detection rate.30 Fusion
biopsy is more accurate than transrectal biopsy, with a higher
cancer detection rate of 55% (vs. 24e40% in standard 12-core bi-
opsy) and more upgrading of the Gleason score in up to 32% of
cases, with increased detection of clinically signiﬁcant higher
Gleason score cancers.36,37Fig. 3. Post-cryoablation ultrasound: image depicting cryoablation cavity in anterior
zone.5. Cryotherapy
The initial experience in focal cryoablationwas reported by Onik
and colleagues.38 In their study, nine men with unilateral prostate
cancer on biopsy underwent cryoablation with preservation of the
neurovascular bundle on the contralateral unaffected side. With a
mean follow up of 3 years, all men had stable PSAs and all six men
who underwent repeat biopsies were negative for pathological
recurrence. Seven of nine men were potent.
Several other clinical studies have investigated the use of focal
cryotherapy since Onik's initial study.39e41While amajority of trials
utilized a hemiablative approach, optimal cryoprobe placement has
yet to be determined (Fig. 1). Computer-based technologists have
strived to develop and improve cryoprobe placement to maximize
destruction of targeted tissue while sparing adjacent noncancerous
tissue42 (Figs. 2 and 3).
There is a lack of consensus on how recurrence is deﬁned after
cryotherapy, and no accepted deﬁnition of PSA failure after primary
therapy, making data on outcomes hard to interpret. Among theFig. 1. Hemi-cryoablation 3T magnetic resonance imaging. T2-weighted image showing atro
showing nonenhancing cavity in lobe.existing literature, it is also difﬁcult to ascertain whether these
patients had true recurrence from missed treatment versus cancer
that was originally missed on staging and biopsy. Lambert et al
reported a 12% biochemical recurrence rate (deﬁned as PSA
nadir > 50%) with 43% with biopsy-proven recurrence on repeat
biopsy. Bahn et al had a low 7% rate of biochemical recurrence with
only 1/25 (4%) men having evidence of cancer when undergoing
repeat biopsy.40 Truesdale et al43 reported a biochemical failure
rate of 27.3% according to the Phoenix deﬁnition of PSA nadir þ2
and a 46% positive rebiopsy rate among cases with suspicion for
recurrence. Most of these recurrences (70e93%) occurred in the
untreated contralateral side, which may indicate more a failure of
initial staging, rather than the treatment.
The largest published experience and outcomes with focal
cryotherapy comes from the Cryo On-Line Data (COLD) registry.
In its latest update, of 1160 patients that had been treatedwith focalphic right lobe after hemi-cryoablation. Dynamic contrast enhancement image (right)
Fig. 4. Post-HIFU 3T magnetic resonance imaging: atrophic prostate total gland post-
HIFU. HIFU, high-intensity focused ultrasound.
S. Marshall, S. Taneja / Prostate International 3 (2015) 35e4138cryoablation, the biochemical recurrence-free rate (ASTRO deﬁni-
tion of three consecutive PSA rises after post-treatment nadir) at 3
years was 75.7%. Prostate biopsy was performed in 14.1%, and
positive in 26.3% of these patients, which comprised only 3.7% (43/
1160) of all treated patients.44
Older trials and reviews reﬂect a combination of older and
newer cryosystems, making the data also difﬁcult to interpret or
apply to current methods. From the COLD registry, urinary conti-
nence (deﬁned as use of 0 pads) was 98.4%, and maintenance of
spontaneous erections was 58.1%. Urinary retention and ﬁstula
rates were both low, with prolonged urinary retention (>30 days)
occurring in six (1.1%) patients, and rectourethral ﬁstula observed
in one (0.1%) patient.44
Focal cryoablation is increasingly used for selected patients with
prostate cancer, with a 10-fold increase in use from 1999 to 2005
based on the COLD registry. Oncological efﬁcacy in the most recent
COLD series update appears similar to that of whole-gland
cryoablation.44
6. High-intensity focused ultrasound
The initial study demonstrating high-intensity focused ultra-
sound (HIFU) success in treating prostate cancer was published in
1995.45 HIFU works by ablating tissue via US-guided application of
mechanical and thermal energy. The two mechanisms of tissue
damage are by the conversion of mechanical energy into heat and
inertial cavitation.
The majority of published results using HIFU have investigated
its efﬁcacy as a whole-gland treatment (Fig. 4). Ganzer and col-
leagues recently reported 14-year follow-up data on oncologicalFig. 5. Candidate for focal laser ablation 3T magnetic resonance imaging. Preoperative T2
anterior TZ tumor.and functional outcomes in 538 men. The biochemical disease-free
rate at 5 years was 81% and at 61% at 10 years.46 Previous studies
have cited biochemical disease-free rate ranging from 45% to 84%
at 5 years and 69% at 7 years, using ASTRO or Phoenix criteria.47 In
the Ganzer study, metastatic disease was reported in 0.4e6% of
low- and intermediate-risk patients, and 15.4% in high-risk pa-
tients. prostate-cancer-speciﬁc death occurred in 18 (3.3%)
patients.46
Based on recent reviews, the most commonly encountered
morbidities after whole-gland therapy include impotence (44%),
urinary incontinence (8%), urinary retention (5.3%), chronic peri-
neal pain (3.4%), and rectourethral ﬁstula (1%).48 Other common
complications include stress urinary incontinence (1e28%), urinary
tract infection (0e58%), urethral/bladder neck stenosis or strictures
(1e31%). For the Ablatherm HIFU device, the rate of complications
has been signiﬁcantly reduced over the years, due to technical
improvements. The rate of urinary retention was <10% and of rec-
tourethral ﬁstula was 0e3%.49
To date, not many studies have used HIFU used as focal therapy.
Muto and colleagues compared 70 patients undergoing whole-
gland HIFU to 29 with unilateral disease undergoing focal HIFU.
At 12 months, there was an 82% negative biopsy rate, with focal
treatment not appearing to compromise cancer control. Urinary
symptoms did not differ signiﬁcantly.50
El Fegoun and colleagues51 reported results of focal HIFU hem-
iablation performed on 12 patients. Median follow-upwas 10 years.
Recurrence-free survival was 90% at 5 years, and 38% at 10 years.
Five patients had salvage therapy with repeat HIFU (n ¼ 1) or
hormonal therapy (n ¼ 4) and there were no metastases. Compli-
cations included one case of urinary retention and two patients
with urinary tract infections.51 Another study by Ahmed et al9 re-
ported results of HIFU hemiablation in 20 patients with unilateral
cancer. On follow-up biopsy of the treated side at 6 months, 89% of
men had negative biopsy. At 12 months follow-up, 95% of men
reported erections sufﬁcient for intercourse and 90% of men were
pad and leak free.9
7. Other approaches
While cryoablation and HIFU are currently the two modalities
with the most long-standing experience in focal therapy, there are
various other treatment strategies currently under investigation.
Focal laser ablation (FLA) is a recent technique that uses laser en-
ergy to ablate MRI visible lesions. The advantage of this approach is
that it can be done with real-time monitoring via MRI, allowing the
surgeon to ensure completeness of treatment as well as avoid vital
structures in order to minimize morbidity (Figs. 5 and 6). A Phase I-weighted image (left) and apparent diffusion coefﬁcient map (right) showing right
Fig. 6. Focal laser ablation 3T MRI: same patient after laser ablation. T2-weighted image (left), apparent diffusion coefﬁcient map (middle), and subtracted DCE (right). Lesion no
longer seen. Small cavity on DCE (arrow). DCE, dynamic contrast enhancement.
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cohort had no evidence of disease after FLA, while 67% of them had
no evidence of disease only at the site of ablation. One patient with
residual disease at the ablation site underwent RP without com-
plications. There were no changes in erectile function or voiding
symptoms.52 Another recent study by Oto et al53 examined nine
patients who underwent FLA. Immediate contrast-enhanced post-
treatment MRI showed a hypovascular defect in eight patients.
Average International Prostate Symptom Score (IPSS) and Sexual
Health Inventory for Men (SHIM) scores did not change signiﬁ-
cantly. MRI-guided biopsy of the ablation zone showed no cancer in
seven patients (78%) and Gleason Grade 6 cancer in two (22%). Self-
resolving perineal abrasion and focal paresthesia of the glans penis
each occurred in one patient.53
Bipolar radiofrequency ablation (RFA) is another technique un-
der investigation that can be performed under TRUS guidance.54e56
The ultrasound images and probe-driving mechanism template are
mated to allow accurate position of the probe so as to precisely
target the regions of the prostate that were mapped during the
biopsy. A specially designed driver mechanism is used to position
the probe to within 0.5 mm of the desired location. Appropriate
insertions of bipolar RFA probes are designed in the planning
process to target the selected regions. Although the FDA has
approved bipolar RFA for the treatment of prostate cancer, no trials
have as yet reported its outcomes.56Fig. 7. Candidate for focal cryoablation 3T magnetic resonance imaging. Preoperative T2-wei
weighted imaging (right) show left anterior transition zone (TZ) lesion.
Fig. 8. Focal cryoablation 3T magnetic resonance imaging. T2-weighted image (left), appare
same patient from prior slide, following focal cryoablation. Atrophy of this region with dec8. Follow-up of patients for assessment of efﬁcacy
The best method to follow patients after focal therapy is
controversial. The current methods generally use follow-up PSA,
MPMRI, and/or biopsy in some combination. In utilizing biopsy as a
follow-up parameter, the rigor of the follow-up should be the same
as the selection biopsy in order to determine treatment efﬁcacy.
The follow-up of focal therapy using MRI is possible, especially
using the DCE sequence as the treated lesion/region no longer en-
hances57 (Figs. 7 and 8). The optimal timing of such imaging de-
pends upon the goal, with immediate imaging at 1 week best
demonstrating the zone of treatment effect and delayed imaging at
6 months demonstrating residual regions of cancer left untreated.
The relative amount of tissue ablated varies greatly in focal
therapy, due to differences in volume, location and Gleason score.
Thus, PSA levels may not be reﬂective, predictable, or comparable
across patients. The ideal PSA nadir is also undeﬁned. It has been
shown that PSA decreases by 30e60% after focal therapy.40,50,58,59
In a study using focal HIFU, the PSA decreased by 80% at 6
months.9 The mean PSA after focal therapy is 2e3 ng/dL.10 Many
groups have used the ASTRO criteria to deﬁne biochemical recur-
rence after focal therapy, to account for variability in PSA due to
benign prostatic hyperplasia, inﬂammation, and residual disease.
The Phoenix deﬁnition is thought to bemore speciﬁc for recurrence
in patients who have had deﬁnitive radiation treatment.10ghted image (left), apparent diffusion coefﬁcient map (middle), and high B on diffusion-
nt diffusion coefﬁcient map (middle), and dynamic contrast-enhanced image (right) in
reased enhancement.
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Focal therapy has the potential to offer an array of treatments
that stand midway between AS and radical therapy for patients
with low-to intermediate-risk disease. Future randomized
studies in focal therapy must critically evaluate candidate se-
lection criteria and robustly answer questions regarding out-
comes and follow-up monitoring. Focal therapy offers a
promising outlook for the future in the treatment of prostate
cancer, with the goal of effectively achieving cancer control while
minimizing morbidity.References
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